Company / FCF Margin
Lineage Cell Therapeutics, Inc. FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
-133.6%
FY2025
5-year range
-1085.3% / -133.6%
FY2021-FY2025
Trend
+46.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
FCF Margin has increased for 4 consecutive years, from -1085.3% in FY2021 to -133.6% in FY2025.
Based on SEC 10-K filings.
-133.6% in FY2025 with a 5-year CAGR of +787.8%.
Improved from -326.9% to -133.6% over the past 2 years.
FCF Margin over time
Growth rates
- 3-Year Change
- +417.0pp
- 5-Year Change
- +787.8pp
- 10-Year Change
- -
Key checks
Key Insights
- Lineage Cell Therapeutics, Inc.'s fcf margin has grown for 4 consecutive years.
- In FY2025, fcf margin increased 46.4% year-over-year.
- Lowest fcf margin in the period was in FY2021.
Company context
Key Data Points
- Altman Z-Score -3.82 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -133.6% | +46.4% |
| FY2024 | -249.0% | +23.8% |
| FY2023 | -326.9% | +40.6% |
| FY2022 | -550.6% | +49.3% |
| FY2021 | -1085.3% | -17.8% |
| FY2020 | -921.4% | -46.2% |
| FY2019 | -630.3% | +31.6% |
| FY2018 | -920.9% | -41.5% |
| FY2017 | -650.7% | +13.3% |
| FY2016 | -750.1% | -4.6% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026